Physician profile
Eric Alan Huerter
NPI 1225133812
$2,085.00
in general payments reported to CMS, 2019-2025
36 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $196 · 2023: $332 · 2024: $267 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $424.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $315.14 | 2019-2023 | Shingrix, Arexvy |
| Amgen INC. | $160.97 | 2019-2025 | Repatha, Evenity, Repatha |
| Pfizer INC. | $94.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.30 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $79.20 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $68.91 | 2019-2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $60.19 | 2024-2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $48.20 | 2019-2020 | |
| Eisai INC. | $47.83 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.37 | 2019-2020 | |
| Shield Therapeutics INC | $40.27 | 2025 | |
| Scilex Pharmaceuticals INC. | $40.18 | 2019 | |
| Medtronic, INC. | $36.96 | 2023 | Venaseal |
| Merck Sharp & Dohme LLC | $36.79 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.57 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.24 | 2023-2024 | Xifaxan |
| Mylan Specialty L.P. | $32.14 | 2019-2020 | |
| Lundbeck LLC | $32.09 | 2024 | Rexulti |
| Grifols USA, LLC | $31.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.44 | 2020-2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $28.43 | 2020-2025 | Zoryve |
| Amarin Pharma, INC. | $28.24 | 2019-2020 | |
| Spr Therapeutics, INC | $25.23 | 2025 | Sprint Pns System |
| Shire North American Group INC | $24.48 | 2019 | |
| Optinose US, INC. | $23.22 | 2024 | |
| Dexcom, INC. | $22.74 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $22.57 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $20.48 | 2019 | |
| Neurelis, INC. | $20.02 | 2024 | Valtoco |
| Regeneron Healthcare Solutions, INC. | $18.13 | 2019 | |
| Philips North America LLC | $17.18 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.79 | 2019 | |
| Ardelyx, INC. | $15.88 | 2025 | Ibsrela |
| Advanced Respiratory, INC | $13.80 | 2020 | |
| Boston Scientific Corporation | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Huerter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.